219 related articles for article (PubMed ID: 30115749)
1. Studying the differential efficacy of postsymptom antitoxin treatment in type A versus type B botulism using a rabbit spirometry model.
Torgeman A; Schwartz A; Diamant E; Baruchi T; Dor E; Ben David A; Pass A; Barnea A; Tal A; Rosner A; Rosen O; Zichel R
Dis Model Mech; 2018 Sep; 11(9):. PubMed ID: 30115749
[TBL] [Abstract][Full Text] [Related]
2. A Novel Rabbit Spirometry Model of Type E Botulism and Its Use for the Evaluation of Postsymptom Antitoxin Efficacy.
Diamant E; Pass A; Rosen O; Ben David A; Torgeman A; Barnea A; Tal A; Rosner A; Zichel R
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29437616
[TBL] [Abstract][Full Text] [Related]
3. A Novel Running Wheel Mouse Model for Botulism and Its Use for the Evaluation of Postsymptom Antitoxin Efficacy.
Schwartz A; Ben David A; Hotoveli M; Dor E; Diamant E; Vivyorka A; Rosen O; Torgeman A; Zichel R
Antimicrob Agents Chemother; 2021 Jul; 65(8):e0042121. PubMed ID: 33972251
[TBL] [Abstract][Full Text] [Related]
4. A Rabbit Model for the Evaluation of Drugs for Treating the Chronic Phase of Botulism.
Torgeman A; Diamant E; Dor E; Schwartz A; Baruchi T; Ben David A; Zichel R
Toxins (Basel); 2021 Sep; 13(10):. PubMed ID: 34678971
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a novel tetravalent botulism antitoxin based on receptor-binding domain of BoNTs.
Shi DY; Lu JS; Mao YY; Liu FJ; Wang R; Du P; Yu S; Yu YZ; Yang ZX
Appl Microbiol Biotechnol; 2023 May; 107(10):3205-3216. PubMed ID: 37058230
[TBL] [Abstract][Full Text] [Related]
6. Symptomatic treatment of botulism with a clinically approved small molecule.
Vazquez-Cintron E; Machamer J; Ondeck C; Pagarigan K; Winner B; Bodner P; Kelly K; Pennington MR; McNutt P
JCI Insight; 2020 Jan; 5(2):. PubMed ID: 31996484
[TBL] [Abstract][Full Text] [Related]
7. A Monoclonal Antibody Combination against both Serotypes A and B Botulinum Toxin Prevents Inhalational Botulism in a Guinea Pig Model.
Snow DM; Cobb RR; Martinez J; Finger-Baker I; Collins L; Terpening S; Syar ES; Niemuth N; Kobs D; Barnewall R; Farr-Jones S; Marks JD; Tomic MT
Toxins (Basel); 2021 Jan; 13(1):. PubMed ID: 33466411
[TBL] [Abstract][Full Text] [Related]
8. Preparation of egg yolk antibodies against BoNT/B and their passive protection in mouse models.
You Z; Yang H; Xin W; Kang L; Gao S; Wang J; Zhang T; Wang J
Hum Vaccin Immunother; 2014; 10(8):2321-7. PubMed ID: 25424938
[TBL] [Abstract][Full Text] [Related]
9. Botulism: cause, effects, diagnosis, clinical and laboratory identification, and treatment modalities.
Dembek ZF; Smith LA; Rusnak JM
Disaster Med Public Health Prep; 2007 Nov; 1(2):122-34. PubMed ID: 18388640
[TBL] [Abstract][Full Text] [Related]
10. A novel strain of Clostridium botulinum that produces type B and type H botulinum toxins.
Barash JR; Arnon SS
J Infect Dis; 2014 Jan; 209(2):183-91. PubMed ID: 24106296
[TBL] [Abstract][Full Text] [Related]
11. Immunological Characterization and Neutralizing Ability of Monoclonal Antibodies Directed Against Botulinum Neurotoxin Type H.
Fan Y; Barash JR; Lou J; Conrad F; Marks JD; Arnon SS
J Infect Dis; 2016 May; 213(10):1606-14. PubMed ID: 26936913
[TBL] [Abstract][Full Text] [Related]
12. Iatrogenic Botulism: A Case Treated With Botulinum Antitoxin.
Gonul Oner O; Gudek HC; Erturk Cetin O; Demir S
Clin Neuropharmacol; 2023 Mar-Apr 01; 46(2):82-84. PubMed ID: 36728838
[TBL] [Abstract][Full Text] [Related]
13. A cell-based alternative to the mouse potency assay for pharmaceutical type E botulinum antitoxins.
Diamant E; Torgeman A; Epstein E; Mechaly A; David AB; Levin L; Schwartz A; Dor E; Girshengorn M; Barnea A; Mazor O; Zichel R
ALTEX; 2022; 39(1):113-122. PubMed ID: 34798660
[TBL] [Abstract][Full Text] [Related]
14. Small Molecule Receptor Binding Inhibitors with In Vivo Efficacy against Botulinum Neurotoxin Serotypes A and E.
Ben David A; Barnea A; Diamant E; Dor E; Schwartz A; Torgeman A; Zichel R
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445283
[TBL] [Abstract][Full Text] [Related]
15. Delayed Antitoxin Treatment of Two Adult Patients with Botulism after Cosmetic Injection of Botulinum Type A Toxin.
Fan KL; Wang YL; Chu G; Leung LP
J Emerg Med; 2016 Dec; 51(6):677-679. PubMed ID: 27687174
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic efficacy of equine botulism antitoxin in Rhesus macaques.
Kodihalli S; Emanuel A; Takla T; Hua Y; Hobbs C; LeClaire R; O'Donnell DC
PLoS One; 2017; 12(11):e0186892. PubMed ID: 29166654
[TBL] [Abstract][Full Text] [Related]
17. In-Vivo Neutralization of Botulinum Neurotoxin Serotype E Using Rabbit Polyclonal Antibody Developed against BoNT/E Light Chain.
Rani S; Ponmariappan S; Sharma A; Kamboj DV; Jain AK
Protein Pept Lett; 2017; 24(6):495-502. PubMed ID: 28260503
[TBL] [Abstract][Full Text] [Related]
18. Protective potential of recombinant non-purified botulinum neurotoxin serotypes C and D.
Moreira C; da Cunha CE; Moreira GM; Mendonça M; Salvarani FM; Moreira ÂN; Conceição FR
Anaerobe; 2016 Aug; 40():58-62. PubMed ID: 27236078
[TBL] [Abstract][Full Text] [Related]
19. Development and preclinical evaluation of a new F(ab')₂ antitoxin against botulinum neurotoxin serotype A.
Yu YZ; Zhang SM; Wang WB; Du Y; Zhu HQ; Wang RL; Zhou XW; Lin JB; Wang S; Yu WY; Huang PT; Sun ZW
Biochimie; 2010 Oct; 92(10):1315-20. PubMed ID: 20600570
[TBL] [Abstract][Full Text] [Related]
20. Iatrogenic botulism cases after gastric and axillary application of botulinum toxin and review of literature.
Eser F; Hasanoğlu İ; Kayaaslan B; Kaya Kalem A; Bilen Ş; Orhan G; Güner R
J Infect Dev Ctries; 2024 Mar; 18(3):480-487. PubMed ID: 38635607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]